DiaPharma is closed until Thursday, January 2. Click here to find your Territory Manager...

News and Events

  • DiaPharma Celebrates hae day 🙂

    Posted: May 15, 2023

    It’s Not Just Support. It’s Solutions. May 16 is hae day 🙂 Join DiaPharma in raising awareness, step by step The annual hae day 🙂 aims to raise awareness worldwide of HAE. Team DiaPharma is getting #Active4HAE! Join us by logging time spent on physical or well-being activities at haeday.org. Read about emerging therapeutic targets…

    Read More

  • Collagen is tough (pun intended), make your life easier with these QuickZyme kits

    Posted: May 4, 2023

    It’s Not Just Support. It’s Solutions.   DiaPharma and QuickZyme Know Matrix Matters! For tissues with lower collagen levels and high matrix effect, analyzing collagen is difficult. QuickZyme therefore developed an assay in which the matrix effect was neutralized to make total collagen analysis suited for more organs or imbedded tissue. The references below are…

    Read More

  • Are your patients getting the proper level of anticoagulation?

    Posted: April 28, 2023

    It’s Not Just Support. It’s Solutions. Measuring Warfarin in Patients with a Lupus Anticoagulant At the recent HTRS 2023 Scientific Symposium, a lively discussion in a Plenary Session was presented titled, “Do We Dare to DOAC?” in which presenters debated the use of DOACs in patients with antiphospholipid antibody syndrome (aPS). For an in-depth review,…

    Read More

  • Why isn’t this being funded?! Product Grant Opportunity from DiaPharma

    Posted: April 28, 2023

    It’s Not Just Support. It’s Solutions. Thoughts from HTRS 2023, and a Grant Opportunity The HTRS 2023 Scientific Symposium gave new insights in hemostasis and thrombosis, from health justice initiatives to the latest in antiphospholipid antibody testing. One thing that stood out was a focus on bleeding and clotting disorders in special populations such as…

    Read More

  • Anticipated NASH Drug Approval will Require Expanded Non-Invasive Testing: NASH-TAG 2023 Takeaways

    Posted: April 19, 2023

    -Contributed by Abi Kasberg, PhD High levels of enthusiasm and excitement were shared at this year’s NASH-TAG meeting in Deer Valley, Utah, regarding the future of the NASH landscape. This was in large part due to the announcement of positive data from two phase 3 clinical trials for new NASH drugs: Madrigal’s Resmetirom and Intercept’s…

    Read More

  • SOT 2023, Recap through a DiaPharma lens

    Posted: April 19, 2023

    -Olivia Stricker, PhD Meetings are back baby!  This was the first event that I have been to since the pandemic where it felt 100% back to normal.  It was great to get back to it and have others there to get back to it with. In heading to Nashville, DiaPharma/I was in search of answers…

    Read More

  • Should Direct Oral Anticoagulants (DOAC) be Used in Individuals with Antiphospholipid Syndrome (aPS) vs Long Term Warfarin Treatment?

    Posted: April 14, 2023

    David L. McGlasson, MS, MLS(ASCP) At the recent HTRS 2023 Scientific Symposium, a lively discussion in a Plenary Session was presented titled, “Do We Dare to DOAC?” The HTRS session was moderated by Ayesha N. Zia MD, MSCS and Bethany T. Samuelson, MD, and included three presenters: Introduction to Science: Stephan Moll, MD, University of…

    Read More

  • Grant Opportunity from DiaPharma

    Posted: April 13, 2023

    Why isn’t this being funded?! Thoughts from HTRS 2023, and a grant opportunity from DiaPharma Jennifer J. Kiblinger Scientific Director The HTRS 2023 Scientific Symposium gave new insights in hemostasis and thrombosis, from health justice initiatives to the latest in antiphospholipid antibody testing. There were lively and insightful debates, even one on how many steel…

    Read More

  • Address Unmet Needs in Type 1 Diabetes Drug Development with These Biomarkers

    Posted: April 11, 2023

    It’s Not Just Support. It’s Solutions. How can blood-based biomarkers enrich your Type 1 Diabetes (T1D) study population? In individuals at high risk for Type 1 Diabetes (T1D), the presence of two or more islet auto-antibodies (AAs), such as those to insulin, GAD65, IA-2, and ZnT8, has been shown to be predictive of the rate…

    Read More

  • View the recording of “Shearly You Can’t Be Serious! T-TAS® 01 for Total Platelet Function”

    Posted: February 24, 2023

    It’s Not Just Support. It’s Solutions. Sorry you missed it! You can still view the recording. Shearly you can’t be serious! T-TAS® 01 for total platelet function T-TAS® 01 PL Assay: One test, one result, one answer for total platelet function Talk to a DiaPharma scientist today to learn more. DiaPharma Group, Inc. 8948 Beckett…

    Read More

  • Explore the Atlas PST – a New Dimension of Platelet Analysis

    Posted: February 23, 2023

    It’s Not Just Support. It’s Solutions. Stasys Atlas PST Easy system for fast, accurate platelet function results Designed to form microclots from whole blood samples to uniquely measure platelet contractile forces, aggregation, and function Fast (< 3 minutes) and accurate results mean more information for your platelet function research Reagents and agonists not needed –…

    Read More

  • Emerging Biomarkers in Alcohol Associated Liver Disease

    Posted: February 7, 2023

    It’s Not Just Support. It’s Solutions.   Non-Invasive Biomarkers for Alcohol Associated Liver Disease Studies Biomarkers of cell death and regeneration, inflammation, and immune response become useful tools as new potential Alcohol Associated Liver Disease (ALD) and Alcohol Associated Hepatitis (AH) treatment options are investigated. Serum biomarkers can provide valuable insights into: Disease severity and…

    Read More

  • You name it, Ceveron® s100 can do it

    Posted: February 3, 2023

    It’s Not Just Support. It’s Solutions.    Discover the Ceveron® s100 The first fully-automated coagulation analyzer to combine classic technologies with high-powered LEDs for fluorescent and quenching resonance transfer assays. Perform clotting, chromogenic, and turbidometric hemostasis assays plus Thrombin Generation Testing, ADAMTS13 activity, and FXIII activity all with one instrument. Why Ceveron® s100? Automate your…

    Read More

  • Axes, Rage, and VR at DiaPharma?

    Posted: February 2, 2023

    It’s Not Just Support. It’s Solutions.    Kicking off 2023 Axes, rage, and VR at DiaPharma? At our national sales meeting, there is! DiaPharma held our national sales meeting in January – it’s a chance to see each other in person, plan the year ahead, and have some fun! DiaPharma staff tried our hands at…

    Read More

  • CHOOSING WISELY – Coagulation Testing Recommendations

    Posted: January 25, 2023

    David L. McGlasson, MS, MLS(ASCP) Choosing Wisely is a United States-based health educational campaign led by the American Board of Internal Medicine Foundation (ABIMF) and the Consumers’ Union to reduce the prevalence of unnecessary diagnostic tests and treatments.1 The Choosing Wisely campaign goal is to disseminate information for clinicians and patients that provides diagnostic care…

    Read More

  • A STEEEEP learning curve: My take home messages from an Alcohol-associated Liver Disease meeting from a newbie

    Posted: January 3, 2023

    – Olivia Stricker, PhD and Commercial Business Development Manager at DiaPharma Group I recently attended the AASLD Emerging Topics in Alcohol-associated Liver Disease conference in Philadelphia, PA. Although I had been researching clinical practices in alcohol-associated liver disease (ALD) for the past 6 months, I quickly realized how limited my perspective was from only consuming…

    Read More

  • The Debate of Early-Liver Transplantation for Alcohol-associated Liver Diseases

    Posted: December 21, 2022

    -Contributed by Abi Kasberg, PhD After recently attending the AASLD Emerging Topics in Alcohol-associated Liver Disease conference, it quickly came to my attention the complexities and challenges that are faced while treating alcohol- associated liver diseases (ALD). For one, current treatment options for ALD are incredibly limited. ALD therapies are disputed in effectiveness and can…

    Read More

  • Because matrix matters! The path to lung disease is paved with MMPs and collagen

    Posted: December 14, 2022

    It’s Not Just Support. It’s Solutions.    DiaPharma and QuickZyme Know Matrix Matters! QuickZyme specializes in collagen assays and MMP activity assays (MMP-2, MMP-7, MMP-8, MMP-9, MMP-14). These assays were developed by scientists to fill an unmet need as an alternative to laborious methods. The assays give a more granular insight to the role that…

    Read More

  • Thank you for visiting us at The Liver Meeting®

    Posted: November 11, 2022

    It’s Not Just Support. It’s Solutions.    DIAPHARMA AND VLVbio THANK YOU! We enjoyed meeting so many of you in-person at the AASLD The Liver Meeting®, and sharing new studies using CK18/K18-M30® and CK18/K18-M65® as blood-based biomarkers in the world of NASH, acute alcohol-associated hepatitis, and DILI. DiaPharma has also added new and unique assay…

    Read More

  • What’s New at DiaPharma?

    Posted: November 9, 2022

    It’s Not Just Support. It’s Solutions.    DiaPharma in the Community DiaPharma staff supports many impactful causes. DiaPharma and our staff proudly sponsor events close to our hearts and our community. Most recently, DiaPharma sponsored Ross’s Race in the Alzheimer’s Association Walk to End Alzheimer’s®, and the Circle Tail Golf Classic for Circle Tail assistance…

    Read More